MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Get Free Report) Director Cristian Luput purchased 22,133 shares of the business's stock in a transaction dated Friday, November 1st. The shares were purchased at an average price of $2.51 per share, for a total transaction of $55,553.83. Following the purchase, the director now owns 389,483 shares of the company's stock, valued at approximately $977,602.33. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink.
MAIA Biotechnology Price Performance
MAIA opened at $2.88 on Tuesday. The firm has a market capitalization of $68.86 million, a PE ratio of -1.77 and a beta of 0.32. MAIA Biotechnology, Inc. has a 12 month low of $0.82 and a 12 month high of $5.99.
MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) last issued its quarterly earnings results on Friday, August 9th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.33) by $0.16. Research analysts expect that MAIA Biotechnology, Inc. will post -1.25 earnings per share for the current year.
Institutional Investors Weigh In On MAIA Biotechnology
The Tesla Trade Is Back In Business
From WealthPress | Ad
If you held shares of Tesla throughout 2024, you know It’s been a year of extreme highs and lows…
But according to our one expert, new yearly highs are on the horizon…
In his words, Tesla is building momentum like in 2020, especially as Trump supports the EV maker.
Which is why we’re emailing you now…
You see, most people will simply buy shares of Tesla ahead of the election…
But as they say “There is more than one way to skin a cat”
In fact, we’ve found another way to play shares of Tesla.
Discover how to trade Tesla, simply follow this link here.
A number of large investors have recently bought and sold shares of the company. Mather Group LLC. grew its position in MAIA Biotechnology by 50,150.0% during the 2nd quarter. Mather Group LLC. now owns 12,060 shares of the company's stock worth $41,000 after purchasing an additional 12,036 shares during the period. Ground Swell Capital LLC purchased a new stake in shares of MAIA Biotechnology in the second quarter worth about $56,000. Finally, Virtu Financial LLC acquired a new stake in MAIA Biotechnology during the first quarter worth about $71,000. Hedge funds and other institutional investors own 5.65% of the company's stock.
About MAIA Biotechnology
(
Get Free Report)
MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
